Developing Breakthrough Therapies for Rare Inflammatory Diseases. Yuval Cohen,Corbus Pharmaceuticals




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Developing Breakthrough Therapies for Rare Inflammatory Diseases. Yuval Cohen,Corbus Pharmaceuticals
Released on: July 01, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In chronic inflammatory diseases, the body is unable to turn off heightened inflammatory responses.
  • Summary
  • Transcript
  • Participants
  • Company
In chronic inflammatory diseases, the body is unable to turn off heightened inflammatory responses. Resunab is designed to trigger the resolution of chronic inflammation by binding to and activating the CB2 receptor on immune cells (in effect, turning inflammation "off"). During BIO 2015, Yuval Cohen, CEO, Corbus, explains to PharmaVentures' Fintan Walton the strategy they are following to take Resunab forward into Phase 11 trials and eventually to market.
In chronic inflammatory diseases, the body is unable to turn off heightened inflammatory responses. Resunab is designed to trigger the resolution of chronic inflammation by binding to and activating the CB2 receptor on immune cells (in effect, turning inflammation "off"). During BIO 2015, Yuval Cohen, CEO, Corbus, explains to PharmaVentures' Fintan Walton the strategy they are following to take Resunab forward into Phase 11 trials and eventually to market.
Yuval Cohen, PhD Chief Executive Officer, Director Yuval Cohen, Ph.D., joined Corbus in July 2013 as Chief Executive Officer. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq CLTX) from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus successfully developed five novel anti-inflammatory drug programs - including two in Phase II - focusing on allergies and autoimmune diseases of the skin, airways, digestive tract and eye. He participated in all stages of the pre-clinical and clinical development from project management to interactions with regulatory bodies and with the investment community in fund raising. In March 2013, Dr. Cohen successfully completed a public listing of Celsus in the United States. Apart from his industry experience, he is also the author of a number of peer-reviewed papers and reviews as well as listed inventor on a number of patents. Dr. Cohen has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. He attained a Bachelor of Science (Honors) from the University of Cape Town (South Africa) before being awarded the prestigious BGF Scholarship from the French foreign ministry to carry out his doctoral studies in Paris.
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. The Company's lead product candidate, Resunabâ„¢, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. Resunab is scheduled to commence three Phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. Resunab also has the potential to treat additional rare, inflammatory diseases.